Ulcerative Colitis Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Global Ulcerative Colitis Market Share and the market is Segmented by Drug Type (Anti-Inflammatory Drugs (Amino salicylates, and Corticosteroids), Anti-TNF biologics, Immuno-suppressants, Calcineurin Inhibitors, and Other Drug Types), Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are provided in terms of value (USD million) for all the above segments.

Ulcerative Colitis Market Size

Single User License
Team License
Corporate License
Book before:
Ulcerative Colitis Market Summary
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 3.75 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Ulcerative Colitis Market Analysis

The ulcerative colitis market size is expected to grow from USD 7.49 billion in 2023 to USD 9.00 billion by 2028, registering a CAGR of 3.75% during the forecast period.

COVID-19 severely impacted various treatment markets, including the ulcerative colitis market, due to an increased preference for COVID-19 treatment, supply chain alterations, and increased research studies on COVID-19 products compared with other treatment products. However, due to the decreased COVID-19 effect on the public, the market players focused on various disease treatments, including ulcerative colitis treatment products. For instance, as per AbbVie Inc's 2022 annual report, the net revenue of Rinvoq (upadacitinib) increased 58% in 2022, which was favorably impacted by recent regulatory approvals and expansion of Rinvoq for the treatment of ulcerative colitis and other treatments. This shows the new approval of ulcerative colitis treatments after the COVID-19 pandemic, which is expected to significantly impact the market over the coming years.

Factors such as the growing burden of ulcerative colitis, increasing patient assistance programs, technological advancements, and research drive the market's growth.

The demand for market products is anticipated to rise due to the growing advances in treating ulcerative colitis. For instance, as per the study report published by Frontiers in Pharmacology in September 2022, the research studies on fecal microbiota transplantation, anti-integrin antibodies, Janus kinase inhibitors, and anti-tumor necrosis factor drugs for ulcerative colitis continued to grow over the coming years which likely increased the demand for more advanced treatment products and drives the market growth over the forecast period.

In addition, the increasing involvement of key players in product development related to the field is anticipated to drive the market's growth. For instance, in May 2023, Janssen Global Services, LLC released new safety and efficacy data from a Phase III trial investigating Tremyfa (guselkumab) in adults with moderately to severely active ulcerative colitis (UC). This large focus of market players on developing new drugs for treatment is expected to boost the market's growth in the future. Additionally, the approval of the drugs is also propelling the market's growth. For instance, in November 2021, Bristol Myers Squibb received marketing authorization from the European Commission for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or are intolerant to either conventional therapy or a biologic agent. Thus, the factors above are expected to boost the market's growth over the forecast period.

However, factors such as high levels of unmet clinical need in ulcerative colitis (UC) and the side effects of medications are expected to impede market growth over the forecast period.

Ulcerative Colitis Market Trends

Immunosuppressants Under the Drug Type Segment is Expected to Have the Largest Growth Over the Forecast Period

Immunomodulators, often called immunosuppressants, are a type of medication used in ulcerative colitis to weaken or modulate the activity of the immune system. The research studies for new immunosuppressants for ulcerative colitis, a type of inflammatory bowel disease, along with the increased focus of key market players in developing these drugs, are expected to have the largest segment growth in the market over the forecast period.

According to the study report published by the Springer Drugs journal in March 2023, novel JAK inhibitors, one of the immunomodulating agents with a more focused effect on JAK-1, have shown promise in the treatment of ulcerative colitis, potentially providing a safer and more successful therapeutic option for patients, particularly those who have previously not responded to traditional treatment options. These advanced agents increase the demand for immunosuppressants with their effectiveness in treating ulcerative colitis, which likely propels the segment's growth over the study period.

Immunosuppressants, such as tacrolimus and azathioprine, are commonly used for ulcerative colitis. As per the study report published by Cureus in May 2022, azathioprine was an effective and affordable medication for ulcerative colitis patients who desired to maintain remission for an extended period. Due to this cost-effective treatment option, the market is expected to grow most over the forecast period.

Ulcerative Colitis Market: Estimated Research Funding for Inflammatory Bowel Disease (USD Million), United States, 2022-2024

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to lead the ulcerative colitis market, owing to the presence of key players and the increasing prevalence of ulcerative colitis in the region, along with the continuing funding for developing innovative solutions for treating ulcerative colitis.

The high focus on research activities by the market players is also contributing to the market's growth. For instance, in August 2022, Teva Pharmaceutical Industries initiated a phase II clinical trial to assess the efficacy and safety of TEV-48574 for Ulcerative Colitis. Thus, the new research studies help increase companies' product portfolio, which is expected to drive market growth over the forecast period in the region.

Additionally, approvals from regulatory authorities such as the United States Food and Drug Administration, Health Canada, and others are also propelling the market's growth. For instance, in May 2021, Bristol Myers Squibb received approval from the United States Food and Drug Administration (FDA) for Zeposia (ozanimod) in the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD). Thus, owing to the abovementioned factors, it is expected to have increased demand for various ulcerative colitis treatment products in the region, which will likely propel the market growth over the forecast period.

Ulcerative Colitis Market  - Growth Rate by Region

Ulcerative Colitis Industry Overview

The ulcerative colitis market is fragmented with various market players. The companies implement certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, that help them strengthen their market position. Some market players include Bausch Health Companies Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc. (Allergan, Inc.), and Novartis AG.

Ulcerative Colitis Market Leaders

  1. AbbVie Inc. (Allergan, Inc.)

  2. Merck & Co., Inc.,

  3. Novartis AG

  4. Bausch Health Companies Inc.

  5. Johnson & Johnson

*Disclaimer: Major Players sorted in no particular order

Ulcerative Colitis Market Concentration
bookmark Need More Details on Market Players and Competitors?
Download PDF

Ulcerative Colitis Market News

  • April 2023: Merck & Co., Inc. agreed to acquire Prometheus Biosciences for USD 200.00 per share in cash for a total equity value of approximately USD 10.8 billion. This agreement allows Prometheus Biosciences to maximize the potential for PRA023, a novel, late-stage candidate for ulcerative colitis, Crohn's disease, and other autoimmune conditions.
  • March 2023: Takeda Pharmaceutical Company Limited received approval from the Japanese Ministry of Health, Labour, and Welfare for its Entyvio Pens (vedolizumab) maintenance therapy for moderate to severe ulcerative colitis.

Ulcerative Colitis Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Global Incidence and Prevalence of Ulcerative Colitis

      2. 4.2.2 Technological Advancements

      3. 4.2.3 Increase in Patient Assistance Programs

    3. 4.3 Market Restraints

      1. 4.3.1 High Levels of Unmet Clinical Need in Ulcerative Colitis (UC)

      2. 4.3.2 Side-effects of Medications

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 5.1 By Drug Type

      1. 5.1.1 Anti-Inflammatory Drugs

        1. 5.1.1.1 Aminosalicylates

        2. 5.1.1.2 Corticosteroids

      2. 5.1.2 Anti-TNF biologics

      3. 5.1.3 Immunosuppressants

      4. 5.1.4 Calcineurin Inhibitors

      5. 5.1.5 Other Drug Types

    2. 5.2 By Disease Type

      1. 5.2.1 Ulcerative Proctitis

      2. 5.2.2 Proctosigmoiditis

      3. 5.2.3 Left-sided Colitis

      4. 5.2.4 Pancolitis or Universal Colitis

      5. 5.2.5 Fulminant Colitis

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc. (Allergan, Inc.)

      2. 6.1.2 Bausch Health Companies Inc.

      3. 6.1.3 Johnson & Johnson

      4. 6.1.4 Merck & Co., Inc.,

      5. 6.1.5 Takeda Pharmaceutical Company Limited

      6. 6.1.6 Teva Pharmaceutical Industries Ltd

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Eli Lilly and Company

      9. 6.1.9 Novartis AG

      10. 6.1.10 Bristol Myers Squibb

      11. 6.1.11 Mitsubishi Tanabe Pharma Corporation

      12. 6.1.12 Sun Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Ulcerative Colitis Industry Segmentation

As per the report's scope, ulcerative colitis is an inflammatory disease of the bowel that causes ulcers in the digestive tract. It affects the innermost lining of the large intestine (colon) and rectum. Symptoms usually develop over time rather than suddenly. The Ulcerative Colitis Market is Segmented by Drug Type (Anti-Inflammatory Drugs (Aminosalicylates, and Corticosteroids), Anti-TNF biologics, Immunosuppressants, Calcineurin Inhibitors, and Other Drug Types), Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Drug Type
Anti-Inflammatory Drugs
Aminosalicylates
Corticosteroids
Anti-TNF biologics
Immunosuppressants
Calcineurin Inhibitors
Other Drug Types
By Disease Type
Ulcerative Proctitis
Proctosigmoiditis
Left-sided Colitis
Pancolitis or Universal Colitis
Fulminant Colitis
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Ulcerative Colitis Market Research FAQs

The Global Ulcerative Colitis Market is projected to register a CAGR of 3.75% during the forecast period (2024-2029)

AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc.,, Novartis AG, Bausch Health Companies Inc. and Johnson & Johnson are the major companies operating in the Global Ulcerative Colitis Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Global Ulcerative Colitis Market.

The report covers the Global Ulcerative Colitis Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Ulcerative Colitis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Inflammatory Bowel Disease Industry Report

Statistics for the 2024 Ulcerative Colitis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Ulcerative Colitis analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Ulcerative Colitis Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)